Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

16.12
+0.66004.27%
Post-market: 16.10-0.0200-0.12%19:53 EDT
Volume:2.66M
Turnover:43.12M
Market Cap:12.50B
PE:-11.19
High:16.72
Open:15.70
Low:15.66
Close:15.46
52wk High:36.91
52wk Low:13.83
Shares:775.37M
Float Shares:129.00M
Volume Ratio:1.15
T/O Rate:2.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4400
EPS(LYR):-1.4439
ROE:-206.10%
ROA:-115.28%
PB:18.97
PE(LYR):-11.16

Loading ...

Reassessing Summit Therapeutics (SMMT) After Sharp Pullback And DCF Upside Potential

Simply Wall St.
·
Jan 30

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin

Reuters
·
Jan 29

BUZZ-Summit rises after FDA accepts marketing application for lung cancer drug

Reuters
·
Jan 29

Summit Therapeutics Shares up 5.5% Premarket After US FDA Accepts Co's Application for Ivonescimab Approval

THOMSON REUTERS
·
Jan 29

FDA Accepts Biologics License Application for Summit Therapeutics' Ivonescimab in EGFR-Mutated NSCLC

Reuters
·
Jan 29

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (Bla) Seeking Approval for Ivonescimab in Combination With Chemotherapy in Treatment of Patients With Egfrm Nsclc Post-Tki Therapy

THOMSON REUTERS
·
Jan 29

Summit Therapeutics Inc: Pdufa Goal Action Date of November 14, 2026

THOMSON REUTERS
·
Jan 29

BUZZ-Guggenheim initiates coverage on Crescent Biopharma with 'buy'

Reuters
·
Jan 21

Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio?

Benzinga_recent_news
·
Jan 19

Alpha Buying: Managing Biotech Risk With Insider Clues

Benzinga_recent_news
·
Jan 16

Jefferies Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Jan 15

Summit Therapeutics Files Marketing Application for Lung Cancer Therapy

MT Newswires Live
·
Jan 12

Summit Therapeutics and GSK Partner to Evaluate Ivonescimab and B7-H3 ADC in Solid Tumors

Reuters
·
Jan 12

Summit Therapeutics Inc - to Supply Ivonescimab, GSK to Manage Clinical Operations

THOMSON REUTERS
·
Jan 12

Summit Therapeutics Announces Clinical Trial Collaboration With GSK to Evaluate Ivonescimab in Combination With GSK’s B7-H3 Antibody Drug Conjugate (ADC)

THOMSON REUTERS
·
Jan 12

Summit Therapeutics Inc - Study Expected to Begin Dosing Patients in Mid-2026

THOMSON REUTERS
·
Jan 12

Summit Therapeutics: Each Party to Maintain Rights to Their Respective Products, & Agreement Mutually Non-Exclusive

THOMSON REUTERS
·
Jan 12

Summit Therapeutics Submits FDA Application for Ivonescimab in EGFR-Mutated NSCLC

Reuters
·
Jan 12

Summit Therapeutics Inc - FDA Decision on Ivonescimab Expected by Q4 2026

THOMSON REUTERS
·
Jan 12

Summit Therapeutics Announces Submission of Biologics License Application (Bla) to U.S. FDA Seeking Approval for Ivonescimab in Combination With Chemotherapy in 2L+ Treatment of Patients With Egfrm Nsclc

THOMSON REUTERS
·
Jan 12